23.10.2012 • News • Lonza • anti-cancer therapeutics • Contract Development And Manufacturing Organizations (CDMO)

Lonza, OncoMed to Collaborate on Anti-Cancer Therapeutics

Lonza and OncoMed Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, announced today an agreement for the development and manufacture of OncoMed's pipeline of anti-cancer stem cell therapeutics.

Under the agreement, Lonza will produce material at its mammalian manufacturing facility in Slough, UK. The multi-product GS SystemLicense provides access to Lonza's GS Gene Expression System and Version 8 Media and Feeds Manufacturing Platform.

OncoMed's pipeline is focused on the development of novel monoclonal antibodies that target cancer stem cells.

CHEManager Spotlight

Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Interview

Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.